期刊文献+

泽桂癃爽联合萘哌地尔治疗良性前列腺增生的效果评价 被引量:3

Evaluation of clinical effect of ZeGuiLongShuang capsules combined with naftopidil on benign prostatic heperplasia
下载PDF
导出
摘要 目的:探讨中成药泽桂隆爽胶囊联合α1受体阻滞剂萘哌地尔治疗良性前列腺增生症(BPH)的疗效。方法:门诊BPH患者140例,随机分为治疗组与对照组,每组70例,治疗组口服泽桂癃爽胶囊,每粒0.4 g,每次2粒,每日3次,每晚睡前联合服用萘哌地尔,每次25 mg,每日1次。对照组仅每晚睡前服用萘哌地尔,每次25 mg,每日1次。均治疗8周。观察治疗组与对照组治疗前后夜尿次数、排尿情况、尿流、射程等症状变化及国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、生活质量评分(QOL)、剩余尿及前列腺质量变化。结果:全部患者肝肾功能、血压及心电图均无异常。治疗8周后两组患者的夜尿次数多、排尿无力、尿流细、射程短等症状均有明显好转。与治疗前比较,两组治疗后IPSS和QOL评分降低(P<0.05),Qmax升高(P<0.05),剩余尿显著减少(P<0.05)。治疗组治疗后IPSS、剩余尿低于对照组治疗后(P<0.01),治疗组治疗后Qmax高于对照组治疗后(P<0.01),前列腺质量与单纯应用泽桂癃爽比较虽略降低,但无显著性差异。结论:中成药泽桂癃爽胶囊与萘哌地尔联合应用治疗BPH,可有效改善患者的主观症状与客观指标,无明显毒副作用。提示两种药物联合应用是治疗轻、中度BPH较为理想的药物。 Objective To study the curative effect of ZeGuiLongShuang capsules combined with naftopidil on benign prostatic hyperplasia (BPH) . Methods 140 cases with BPH were randomly divided into treatment group and control group. The patients in treatment group were given ZeGuiLongShuang capsules (once 2 tablets, 3 times a day) combined with naftopidil (once 25 mg, once a day before sleeping). The patients in control group were given only naftopidil (once 25 rag, once a day before sleeping). Internatianal-prognosic-scoring-system (IPSS), uroflowmetry-max (Qmax), Quality-of-life (QOL), residual urine and weight of prostate before and after treatment were detected. Results IPSS, Qmax, QOL and residual urine changed in two groups. IPSS, Qmax, QOL and residual urine in treatment group were more significant than those in control group (P〈0.05). There was little change of weight of prostate. Conclusion There is no remarkable side effect of ZeGuiLongShuang capsules combined with naftopidil. ZeGuiLongShuang capsules combined with naftopidil is highly effective for BPH by decreasing rational symptom and objective index and improving the life quality of patients with BPH.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2009年第5期936-939,共4页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅科技发展计划项目(重点)资助课题(20050908-4)
关键词 前列腺增生 中成药 泽桂隆爽胶囊 萘哌地尔 prostatic heperplasia chinese patent drugs medicine ZeGuiLongShuang capsules Naftopidil
  • 相关文献

参考文献11

二级参考文献103

共引文献80

同被引文献75

  • 1刘丹,白雪,刘桂敏,樊晓蕾,唐田,于淑俊,刘柘君,江波,刘振权.前列腺增生症发病机制的研究进展[J].实用临床医药杂志,2021,25(5):112-117. 被引量:33
  • 2高瞻,伦立军,邵魁卿,沈建武,李奇,张军跃.前列欣胶囊联合盐酸坦洛新缓释胶囊治疗湿热瘀阻型前列腺增生疗效观察[J].湖南中医药大学学报,2011,31(10):17-20. 被引量:8
  • 3Shah HN, Hegde SS, Shah JN, et al. Simultaneous transurethral cys-tolithotripsy with holmium laser enucleation of the prostate : a prospective feasibility study and review of literature [J]. BJU Int, 2007,99(3 ):595 - 600.
  • 4Rowhrborm CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia [ M ]. PA: W. B, Saun- ders Company, 2002 : 1 297 - 1 330.
  • 5Hutchisona A, Farmer R, Verhamme K, et al. Tre efficacy of drug for the treatment, LUTS LBPA a, study in 6 European [ J ]. Eur Urol, 2007,5 1 ( 1 ) : 207 - 215.
  • 6Fourcade RO, Th6ret N, Tai'ebc, et al. Profile and management of Patients treated for the first time for lower urinary tract symptoms/benign Prostatic hyperplasia in four European countries [ J ]. BJU Int, 2008, 101 ( 9 ) : 1 111-1 118.
  • 7左澄章.泽桂癃爽胶囊为主治疗前列腺增生症57例[J].现代医药卫生,2001,17(1):41.
  • 8Higgins J, Green S. Cochrane handbook for systematic reviews of interven- tions. Version 5.1.0 Updated March 2011 [ EB/OL] . http ://www. cochrane, org/training/cochrane - handbook.
  • 9Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta - adrenoceptor subtypes and their functional roles in hu- man normal and obstructed bladders[J]. J Urol, 2003, 170(2 Pt 1): 649 - 653.
  • 10林文彬,汤平.α1-受体阻滞剂联合泽桂癃爽治疗良性前列腺增生的疗效观察[J].实用医学杂志,2008,24(12):2155-2156. 被引量:5

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部